Saudi Pharmaceutical Industries and Medical Provides Firm – Pharmaceutical
an announcement Ahmed Al -Jadeea Vice Chairman and Managing Director ofSaudi Pharmaceutical Industries and Medical Provides Firm – PharmaceuticalThe corporate plans to register greater than 8 new medication this 12 months, whereas aiming to register greater than 15 new pharmaceutical business product from vital merchandise within the 12 months 2026.
Al -Jadeea mentioned in an interview with CNBC Arabia, that the corporate presently has greater than 24 agreements with worldwide corporations to fabricate its medicines within the firm, along with some native corporations.
Al -Jadeea revealed that the corporate plans to increase and enter the African markets and European markets within the close to future, indicating that the corporate is presently in 18 international locations alongside the Kingdom of Saudi Arabia.
On the brand new manufacturing unit, the Vice -Chairman of the Pharmaceutical Board of Administrators acknowledged that the corporate began to launch the primary absolutely manufactured business product in its new manufacturing unit specializing within the manufacture of excessive -purity oncology and medicines, which is the primary of its sort within the area, including that the settlement signed with the Worldwide Firm of Astrazenica is a step to open horizons to file and localize new medication in Saudi Arabia.
He defined that over a interval of 5 years it’s anticipated that the income from the brand new manufacturing unit exceeds greater than twice the investments of 272 million riyals, along with enhancing the corporate’s profitability by advantage of the manufacture of such excessive -value efficient medication and enhancing the goal revenue, in mild of the expectations that the manufacturing unit produce greater than 300 million manufacturing models yearly sooner or later, which can be mirrored in gross sales and profitability, and that the corporate’s market share of cancerous medication rises from Lower than 1 % presently to 10 % sooner or later.
Requested concerning the money liquidity of the corporate, he acknowledged that it’s greater than 260 million riyals presently and a big a part of it’s allotted to enlargement and funding in analysis and improvement, and to register different vital medication and vaccines, along with paying the corporate’s money owed to enhance the extent of money circulate, indicating that the corporate’s monetary place is nice and has vital financial institution amenities and there’s no present debt and have to pay.
Based on knowledge numbersFinal July, the Pharmaceutical Firm launched its new manufacturing unit that focuses on the manufacture of excessive poisonous tumors and medicines, in Al -Qassim at a complete price of 272 million riyals, with the manufacturing of the primary commerce batch in August 2025 AD.
